On 16 April 2026 the FDA removed BPC-157 and 11 other peptides from Category 2, and a Pharmacy Compounding Advisory Committee (PCAC) hearing on 23 and 24 July 2026 is now reviewing whether to add BPC-157, alongside TB-500, KPV, MOTS-C, DSIP, Semax and Epitalon, to the 503A "positive bulks list" (see our FDA PCAC July 2026 explainer)
If we can boost the activity of anti-oxidant genes that help stave off this damage, then we should be able to delay the deterioration of our tissues and our DNA, thus extending longevity
Medications like sedatives (if approved by a doctor)
No expensive labels just great quality Peptides at great prices
One aspect I personally pay attention to as a fellow manufacturer is the scale of Bo Internationals formulation and production capabilities
In practice, the functional tests are more expensive, and laboratories dont have the budget to do a lot of these functional tests